Fiber-derived butyrate and the prevention of colon cancer Christian A Hassig, Jeffrey K Tong and Stuart L Schreiber Inhibition of the enzyme histone cleacetylase by butyrate results in the direct transcriptional upregulation of the cyclin-dependent kinase inhibitor p21KipVWAFl. We discuss a small-molecule-mediated signaling pathway to explain the suspected anti-colon-cancer properties of fiber-derived butyrate.
Fiber, butyrate and colon cancer
Studies relating diet to oncogenesis suggest a correlation between fiber intake and the occurrence of colorectal cancer (for reviews see [l] ). Experiments focusing on the role of dietary fiber in colonic homeostasis indicate the importance of fiber-derived fermentation products produced by anaerobic microflora within the lumen of the large intestine [l] . In particular, the microbial production of a short-chain fatty acid, butyric acid, appears to be important for proper epithelial cell regulation [l] . Unfortunately, attempts to determine precisely the connection between fiber, butyrate and colon cancer have been complicated by the experimental challenges inherent in studying whole organisms and the inability to reproduce in aivo conditions accurately in tissue culture. Butyrate serves as a primary energy source for colonocytes [l] , and numerous studies on human biopsies and animal subjects indicate that butyrate has a proliferative effect on normal colonic epithelium (reviewed in [l] ). Nevertheless, butyrate has anti-proliferative and differentiationinducing effects on various human colon carcinoma cell lines, as well as on other normal and neoplastic cells, at the physiological (millimolar) concentrations obtained in Z&JO [l-3] . Despite the apparent discrepancy between in viva and in vitro studies, the anti-growth activity of butyrate on tissueculture cells has led to the hypothesis that butyrate protects against colon cancer by promoting differentiation, cell-cycle arrest and apoptosis of transformed colonocytes [l] .
The treatment of mammalian cells Zn &ro with low millimolar concentrations of butyrate causes pleiotropic effects on cellular physiology, including changes in the cell membrane, the cytoskeleton, the cell cycle and gene transcription [4] . At least part of the effects induced by butyrate can be attributed to the direct inhibition of the enzyme histone deacetylase (HDAC) [S] . Reversible acetylation of the Eamino groups of lysine residues on the amino-terminal domains of histones is important for nucleosome assembly, chromatin structure and transcriptional regulation (for reviews see [6-S]). Although the precise mechanism(s) and downstream effects of histone acetylation are poorly understood, a hallmark of HDAC inhibition is cell-cycle arrest and the induction of cellular differentiation (reviewed in [9] ).
The possibility that butyrate-mediated inhibition of HDAC is, in part, responsible for the effects seen on cells in vitro is supported by studies using other HDAC inhibitors that mimic the cytological effects of butyrate. The inhibitors, which are microbial metabolites, were initially identified by their ability to revert oncogenic tumor cells to a normal, detransformed morphology (reviewed in [9] ). The insightful observation that one of these detransforming agents, trichostatin A (TSA), was in fact a highly potent (nanomolar Ki) inhibitor of an HDAC activity in vitro and an inducer of histone hyperacetylation in &a paved the way for the discovery of a variety of natural products with HDAC-inhibitory properties ( Figure 1) [9-121. These findings also led to the purification and cloning of HDACl using the HDAC inhibitor trapoxin B (TPX) as a molecular probe [13] . These and subsequent studies using HDAC inhibitors indicated a role for HDAC in control of the Gl/S and G'2/M transitions of the cell cycle, as well as in cellular differentiation and senescence [9, 14] .
The recent demonstration that histone acetyltransferases (HATS) and HDACs are transcriptional regulators [6, 8, 15, 16] provides evidence to support the argument that cytological changes induced by HDAC inhibitors are the downstream effects of altered transcription. In general, HDAC inhibitors specifically upregulate or downregulate the transcription of genes linked to cell proliferation and differentiation, such as myc [6, [17] [18] [19] ,fos [17] , and the gene encoding gelsolin [9] , rather than altering the transcription of housekeeping or constitutive genes, such as the gene encoding GAPDH (see [6] and references therein). The effects of deacetylase inhibitors on cellular processes vary depending on the cell type and the micro-environment of the cell. In the colon, butyrate has the capacity to act as a signaling molecule, being able to traverse the cell membrane of colonocytes, bind to its cognate receptor HDAC, and mediate effects on gene transcription, resulting in dynamic changes in cell physiology.
Induction of p21 by histone deacetylase inhibitors
Among the genes that are directly transcriptionally upregulated in cells treated with butyrate or other HDAC Figure 1 Histone [33] . Given the prominent role of ~21 in cell-cycle control and cellular differentiation, and the phenotypic similarities between pZ1 induction and HDAC inhibition, it is possible that direct upregulation of ~21 is primarily responsible for the cytological effects of HDAC inhibitors. The abundance of naturally occurring HDAC inhibitors and their ability to disrupt the transcription of cell-cyclespecific genes suggest a convergence of microbial evolution towards a common cellular target, HDAC, and emphasize the importance of this enzyme in the cell cycle and cellular differentiation.
Potentially, combinatorial chemistry could be used to identify novel HDAC inhibitors for use in the study of histone acetylation and for use as possible drugs in the treatment of certain cancers. These mapping experiments suggest that a promoter lacking the putative YYl-binding site retains sensitivity to butyrate. Unlike the native p21 gene, however, which is strongly induced by butyrate within 3 hours, recombinant reporter genes containing truncated forms of the p21 promoter require significantly longer time periods of butyrate treatment before showing detectable levels of induction [ZO] . The discrepancy in the time courses may reflect the potential problems associated with studying chromatin regulation in artificial transcription systems. It will be necessary to study the native ~21 promoter in its natural chromatin context to ascertain the involvement of p2 1 regulatory elements in maintaining particular acetylation states.
The conserved architecture of the native ~21, osteocalcin and calbindin-D,,,, VDRE/YYl promoter elements suggests the potential for a related mechanism of transcriptional regulation in which certain vitamin-D-responsive genes recruit YYl and an associated HDAC to enhance transcriptional silencing. The system described here provides two independent signaling mechanisms for altering transcription of the pZ1 gene. In one case 1,25-dihydroxyvitamin D, binds to the VDR, thereby facilitating the binding of VDR to DNA and the subsequent transcriptional activation of ~21. In the other case, butyrate binds to a targeted HDAC and inhibits its transcriptional repression function, leading to ~21 Figure 2 transcription. The similarities of these small moleculedependent signaling pathways are shown in Figure 3 . We have compiled the available data and note an intriguing correlation between WI-regulated genes and sensitivity to HDAC inhibitors (Table 1) . Genes repressed by YYl are activated by deacetylase inhibitors, whereas genes activated by YY1, such as cyc.kz DI, are downregulated by HDAC inhibitors. This is consistent with both a positive and a negative role for HDACs in transcription (for review see [6, 9, 15] ). Not all promoters affected by deacetylase inhibitors contain both a YYl-binding site and a VDRE, however, and further experiments are warranted in order to determine the generality of these observations and the precise role for each component involved. More recent advances in transcript-array technology might aid in the identification of genes transcriptionally altered by HDAC inhibitors and might also provide a method of determining potential differences in HDAC-inhibitor specificities. For example, the HDAC family members may regulate different genes allowing for the possibility of inhibitors that affect only a subset of HDAC-regulated genes, similar to the differential effects mediated by steroid hormones in transcription.
Interpretation of data derived from HDAC inhibitor studies is complicated by the possibility of indirect transcriptional Figure  3 effects caused by hyperacetylation. Furthermore, not all genes directly influenced by HDACs will require YY1, nor is YY1 necessarily acting alone in recruiting HDACs. HDACs are thought to associate with the nuclear co-repressor, N-CoR, and the related SMRT (silencing mediator of retinoid and thyroid hormone receptors) proteins, as well as with the mSin3 co-repressor, to form a multi-protein transcriptional regulatory complex. Evidence suggests that (a) these macromolecular complexes are recruited by nuclear receptors and by the Mad family of E-box DNA-binding transcription factors [6, 15] . Interestingly, YY1 associates with the coactivator ~300 [41], which has recently been shown to possess both an associated and an intrinsic HAT activity [15, 16] . YYl might therefore indirectly mediate both acetylation and deacetylation at certain promoters. It is unknown if YYl associates with both ~300 and HDAC simultaneously. Whether cells not expressing p21 will be affected by deacetylase inhibitors remains to be tested.
Conclusions and prospects
The potential anti-colon-cancer properties of fiber can be linked to a small-molecule signaling pathway involving butyrate, a by-product of fiber-metabolizing bacteria within the colon, and its cellular target HDAC. Butyrate inhibits the enzymatic activity of HDAC, resulting in changes in the transcription of specific genes, including the induction of the cyclin-dependent kinase inhibitor pZl/Cipl/WAFl. Both inhibition of HDAC and expression of pZ1 result in cell-cycle arrest and differentiation, suggesting that induction of p21 is a pivotal event in HDAC inhibitor-mediated cell-cycle arrest. Experiments suggest that both targeted and non-targeted deacetylation of the ~21 promoter by HDAC may be important for the transcriptional repression of ~21. We speculate that the DNA-binding transcription factor YYl negatively regulates ~21 in part by recruiting HDAC to a proposed YYl-binding site in the promoter of the pZ1 gene. Butyrate may therefore alleviate repression of pZ1 by inhibiting a YYl-targeted HDAC. The mechanism is similar to that used by steroid hormones in activating signaling pathways that lead to modified transcription of target genes. In both cases, a membrane-permeable small molecule binds to a protein involved in targeted gene regulation, thus altering the transcription of specific genes. The further study of the mechanism of HDAC inhibitormediated cell-cycle arrest could lead to the design of other potent small-molecule HDAC inhibitors with potential application in colon-cancer therapies.
